The influence of dopamine &bgr;-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study

Recent studies have suggested that heterogeneity in the level of dopamine activity and function might be useful for identifying a subgroup of cocaine-dependent patients responding better to dopamine-enhancement pharmacotherapy. Here we hypothesized that response to levodopa/carbidopa treatment would be greater in patients with genetically determined low levels of the dopamine metabolizing enzyme dopamine &bgr;-hydroxylase (D&bgr;H). Seventy-one cocaine-dependent patients who participated in a 12-week randomized double-blind placebo-controlled trial of levodopa/carbidopa were genotyped for the D&bgr;H gene (DBH) polymorphism rs1611115. Our results showed that for patients with the low D&bgr;H activity genotypes (CT/TT) who received levodopa, the odds of having cocaine-positive urine decreased significantly over treatment compared with placebo-treated patients with the CT/TT genotypes (P=0.004). Individuals with the normal D&bgr;H activity genotype (CC) showed no differential response to levodopa. These preliminary results need to be confirmed in a larger sample focusing on the DBH polymorphism.

[1]  L. Amato,et al.  Dopamine agonists for the treatment of cocaine dependence. , 2015, The Cochrane database of systematic reviews.

[2]  G. Gessa,et al.  The dopamine beta‐hydroxylase inhibitor nepicastat increases dopamine release and potentiates psychostimulant‐induced dopamine release in the prefrontal cortex , 2014, Addiction biology.

[3]  T. Kosten,et al.  DBH gene as predictor of response in a cocaine vaccine clinical trial , 2013, Neuroscience Letters.

[4]  T. Kosten,et al.  Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine β-Hydroxylase , 2013, Biological Psychiatry.

[5]  F. Moeller,et al.  Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. , 2010, Experimental and clinical psychopharmacology.

[6]  R. A. Sewell,et al.  REVIEW: Norepinephrine and stimulant addiction , 2009, Addiction biology.

[7]  Joseph G. Ibrahim,et al.  Missing data methods in longitudinal studies: a review , 2009 .

[8]  F. Moeller,et al.  Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. , 2008, Drug and alcohol dependence.

[9]  R C Elston,et al.  A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. , 2001, American journal of human genetics.

[10]  S. Amur,et al.  Biomarkers for the Development of New Medications for Cocaine Dependence , 2014, Neuropsychopharmacology.